Aurora Spine Corporation
ASAPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.47 | -7.13 | 0.32 | -0.01 |
| FCF Yield | 2.29% | -6.90% | -10.78% | -17.67% |
| EV / EBITDA | 143.02 | -52.38 | -49.84 | -9.85 |
| Quality | ||||
| ROIC | 4.14% | -16.72% | -18.43% | -31.43% |
| Gross Margin | 60.55% | 56.55% | 52.49% | 45.84% |
| Cash Conversion Ratio | -0.95 | 0.56 | 1.04 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.69% | 11.25% | 19.83% | -1.85% |
| Free Cash Flow Growth | 135.06% | 41.83% | 14.70% | -1,062.92% |
| Safety | ||||
| Net Debt / EBITDA | 16.62 | -6.45 | -5.06 | 0.51 |
| Interest Coverage | 2.00 | -8.08 | -8.21 | -16.17 |
| Efficiency | ||||
| Inventory Turnover | 1.92 | 1.77 | 2.31 | 3.02 |
| Cash Conversion Cycle | 176.00 | 194.27 | 101.38 | 56.60 |